Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Bibliographic Details
Main Authors: Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue, Jiwei Huang
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Communications
Online Access:http://link.springer.com/article/10.1186/s40880-019-0405-5

Internet

http://link.springer.com/article/10.1186/s40880-019-0405-5

Similar Items